A Proteomics Dive into Cause of Frontotemporal Dementia
Proteomics and protein-protein interaction research may yield clues to etiology, tracking, and treatment of granulin-related and other forms of FTD/ALS.
ALL NEWS
5779 RESULTS
Sort By:
- Most Recent
- Most Commented
Society for Neuroscience Annual Meeting 2019
Not Just Blood Pressure—Dietary Salt Linked to Tau Phosphorylation Time to Try Again: Gene-Based Therapy for Neurodegeneration Gene Therapies Enter Trials for Many Brain Pathologies—What about AD? Organized around 10 major themes, this year’s annual ...
At Least We Know These Don’t Work: Negative Trials at CTAD
Null results ended the development of the neuroprotective drugs edonerpic and abeotaxane, the AMPA receptor modulator S47445, and the dietary formulation tricaprilin.
Minocycline Does Not Work in Mild Alzheimer’s Disease
Based on preclinical data, researchers gave this antibiotic a shot in a two-year clinical trial. It did nothing to slow cognitive decline.
Experts Slam Marketing of Tramiprosate (Alzhemed) as Nutraceutical
The Canadian pharmaceutical company Bellus Health has begun to sell the would-be prescription drug tramiprosate over the counter as a nutritional supplement...
Gosuranemab, Biogen’s Anti-Tau Immunotherapy, Does Not Fly for PSP
In PASSPORT study, the antibody failed to slow progressive supranuclear palsy. Alzheimer’s trial to continue.
Move Over Aβ, CSF P-Tau Tells Us There’s Plaque in the Brain
At AAIC, researchers touted phospho-tau species, especially p217 and p181. They tick up in CSF as an early response to amyloid accumulation.
Move Over CSF, P-Tau in Blood Also Tells Us There’s Plaque in the Brain
At this year’s AAIC, no sooner had scientists reported that phospho-tau in the CSF might reflect early responses to amyloid, than they reported parallel data for phospho-tau in blood.
Synaptic Proteins in CSF: New Markers of Cognitive Decline?
Protein levels track with cognitive function and can distinguish Alzheimer’s patients from controls.
Blood Tests of Phospho-Tau, Aβ42, Track With Brain Amyloid
Using mass spectrometry to detect teensy amounts of phospho-tau species in plasma, researchers reported that p-tau-217 and p-tau-181 picked out people with Aβ pathology. Differences between groups appear to be huge. An MS-based test for plasma Aβ42 corresponded to brain amyloid, and is going in for regulatory approval.
Geneticists Seek Out Rare Contributors to Alzheimer’s
New genes linked to early and late-onset AD offer up mechanistic insight, potential targets for treatment.
Innate Immune Cells Enlisted to Clear Amyloid, Fight Disease
Scientists are tweaking immune pathways to scavenge amyloid and curb symptoms in Alzheimer’s mice.
Going Indirect: Can Therapies Halt Alzheimer’s from Outside the Brain?
Apabetalone, an epigenetic drug that tamps down vascular inflammation, slowed cognitive decline in people with MCI. A new statistical analysis of results from AMBAR claimed the plasma-exchange therapy might boost cognition by removing pathogenic proteins from blood.
Alzheimer's Disease Research Summit 2019
NIH Summit Sets Agenda for AD-Related Dementias Alzheimer's Disease Research Summit 2019 ...
Senate Ups Funding for Alzheimer’s Research by $350 million for 2020
Bringing the total NIH funding for Alzheimer’s research up to $2.8 billion, the Senate continued its steady upward climb in spending for the disease.
Current Filters
- Date Range : All x